The epidemiology of virus transmission by plasma derivatives: Clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1

Transfusion

Volumn 39, Issue 11-12, 1999, Pages 1160-1168

  Tabor, E ^a,b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 12A; BLOOD CLOTTING FACTOR 9;

HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION RISK; PLASMA TRANSFUSION; REVIEW; RISK ASSESSMENT; VIRUS TRANSMISSION;

FEMALE; HEPATITIS B; HEPATITIS C; HIV INFECTIONS; HUMANS; PLASMA; PREGNANCY; SERUM ALBUMIN; VIRUS DISEASES;

EID: 0032756734     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.1999.39111160.x     Document Type: Review

References (57)

1. Blood plasma safety: plasma product risks are low if good manufacturing practices are followed. Publication GAO/ HEHS-98-205. Washington: General Accounting Office, 1998:21.
2. Alter HJ, Holland PV, Purcell RH. The emerging pattern of post-transfusion hepatitis. Am J Med Sci 1975;270:329-34.
3. Paine RS, Janeway CA. Human albumin infusions and homologous serum jaundice. JAMA 1952;150:199-202.
4. Gellis SS, Neefe JR, Stokes J Jr., et al. Chemical, clinical and immunological studies on the products of human plasma fractionation. XXXVI. Inactivation of the virus of homologous serum hepatitis in solutions of normal human serum albumin by means of heat. J Clin Invest 1948;27:239-44.
5. Murray R, Diefenbach WC. Effect of heat on the agent of homologous serum hepatitis. Proc Soc Exp Biol Med 1953;84:230-1.
6. Murray R, Diefenbach WC, Geller H, et al. The problem of reducing the danger of serum hepatitis from blood and blood products. N Y State J Med 1955;55:1145-50.
7. Barker LF, Murray R. Relationship of virus dose to incubation time of clinical hepatitis and time of appearance of hepatitis-associated antigen. Am J Med Sci 1971;263:27-33.
8. Pennell RB. The distribution of certain viruses in the fractionation of plasma. In: Hartman FW, LoGrippo GA, Matteer JG, Barron J, eds. Hepatitis frontiers, a Henry Ford Hospital international symposium. Boston: Little, Brown, 1957:297-310.
9. Soulier JP, Blatix C, Courouce AM, et al. Prevention of virus B hepatitis (SH hepatitis). Am J Dis Child 1972;123:429-34.
10. Shikata T, Karasawa T, Abe K, et al. Incomplete inactivation of hepatitis B virus after heat treatment at 60C for 10 hours. J Infect Dis 1978;138:242-4.
11. Pattison CP, Klein CA, Leger RT, et al. An outbreak of type B hepatitis associated with transfusion of plasma protein fraction. Am J Epidemiol 1976;103:398-407.
12. Pattison CP, Klein CA, Leger RT, et al. Field studies of type B hepatitis associated with transfusion of plasma protein fraction. In: Sgouris JT, Rene A, eds. Proceedings of the Workshop on Albumin. DHEW Publication no. 76-925. Bethesda: National Institutes of Health, 1976:315-9.
13. Tabor E, Gerety RJ. The chimpanzee animal model for non-A, non-B hepatitis: new applications. In: Szmuness W, Alter HJ, Maynard JE, eds. Viral hepatitis: 1981 International Symposium. Philadelphia: Franklin Institute Press, 1982:305-17.
14. Hilfenhaus J, Gröner A, Nowak T, Weimer T. Analysis of human plasma products: polymerase chain reaction does not discriminate between live and inactivated viruses. Transfusion 1997;37:935-40.
15. McDougal JS, Martin LS, Cort SP, et al. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. J Clin Invest 1985;76:875-7.
16. Uemura Y, Yang YH, Heldebrant CM, et al. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin. Vox Sang 1994;67:246-54.
17. Coombs RW, Collier AC, Allain JP, et al. Plasma viremia in human immunodeficiency virus infection. N Engl J Med 1989;321:1626-31.
18. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type 1 in the blood of infected persons. N Engl J Med 1989;321:1621-5.
19. Piatak M Jr, Saag MS, Yang LC, et al. Determination of plasma viral load in HIV-1 infection by quantitative competitive polymerase chain reaction. AIDS 1993;7(Suppl 2):S65-S71.
20. Piatak M Jr, Yang LC, Luk KC, et al. Viral dynamics in primary HIV-1 infection (letter). Lancet 1993;341:1099.
21. Ercoli L, Sarmati L, el-Sawaf G, et al. Plasma viremia titration and RNA quantitation in ICD-p24 negative HIV type-1-infected patients. AIDS Res Hum Retroviruses 1995;11:1203-7.
22. Renger F, Porst H, Frank KH, et al. [On the epidemiology, clinic, immunology and morphology of non-A/non-B hepatitis.] Z Arztl Fortbild (Berl) 1981;75:894-7 [NIH Library Translation #NIH 82-18].
23. Meisel H, Reip A, Faltus B, et al. Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet 1995;345:1209-11.
24. Power JP, Lawlor E, Davidson F, et al. Molecular epidemiology of an outbreak of infection with hepatitis C virus in recipients of anti-D immunoglobulin. Lancet 1995;345:1211-3.
25. Foster PR, McIntosh RV, Welch AG. Hepatitis C infection from anti-D immunoglobulin (letter). Lancet 1995;346:372-3.
26. Yei S, Yu MW, Tankersley DL. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion 1992;32:824-8.
27. Finlayson JS, Tankersley DL. Anti-HCV screening and plasma fractionation: the case against. Lancet 1990;335: 1274-5.
28. Tabor E, Gerety RJ. Transmission of hepatitis B by immune serum globulin (letter). Lancet 1979;2:1293.
29. Gerety RJ, Smallwood LA, Tabor E. Hepatitis B immune globulin and immune serum globulin (letter). N Engl J Med 1980;303:529.
30. Hoofnagle JH, Waggonner JG. Hepatitis A and B virus markers in immune serum globulin. Gastroenterology 1980;78:259-63.
31. Murray R, Ratner F. Safety of immune serum globulin with respect to homologous serum hepatitis. Proc Soc Exp Biol Med 1953;83:554-5.
32. Barker LF, Maynard JE, Purcell RH, et al. Hepatitis B virus infection in chimpanzees: titration of subtypes. J Infect Dis 1975;132:451-8.
33. Yu MW, Mason BL, Yei S, Tankersley DL. Detection and quantitation of HCV-RNA in immune globulins produced by Cohn-Oncley fractionation of human plasma. In: Nishioka K, Suzuki H, Mishiro S, Oda S, eds. Viral hepatitis and liver disease. Tokyo: Springer-Verlag, 1994:574-7.
34. Cristiano K, Pisani G, Wirz M, Gentili G. Testing of immunoglobulin products for hepatitis C virus by polymerase chain reaction: importance of an internal control (letter). Transfusion 1997;37:878.
35. Da Silva Cardoso M, Koerner K, Epple S, Kubanek B. Safety of blood products derived from plasma pools: the positive impact of anti-HCV screening on the quality of such products. Vox Sang 1996;71:184-6.
36. Tankersley DL, Mason BL, Guo ZP, Yu MW. Viral safety of intravenous immunoglobulin. In: Kazatchkine MD, Morell A, eds. Intravenous immunoglobulin research and therapy. London: Parthenon, 1996:3-9.
37. Lever AM, Webster AD, Brown D, Thomas HC. Non-A, non-B hepatitis occurring in agammaglobulinaemic patients after intravenous immunoglobulin. Lancet 1984;2:1062-4.
38. Björkander J, Cunningham-Rundles C, Lundin P, et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 1988;84:107-11.
39. Lane RS. Non-A, non-B hepatitis from intravenous immunoglobulin (letter). Lancet 1983;2:974-5.
40. Bjoøro K, Froøland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-11.
41. Bresee JS, Mast EE, Coleman PJ, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA 1996;276:1563-7.
42. Yu MW, Mason BL, Guo ZP, et al. Hepatitis C transmission associated with intravenous immunoglobulins. Lancet 1995;345:1173-4.
43. Nübling CM, Willkommen H, Löwer J. Hepatitis C transmission associated with intravenous immunoglobulins (letter). Lancet 1995;345:1174.
44. Zuck TF, Preston MS, Tankersley DL, et al. More on partitioning and inactivation of AIDS virus in immune globulin preparations (letter). N Engl J Med 1986;314:1454-5.
45. Safety of therapeutic immune globulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection. MMWR Morb Mortal Wkly Rep 1986;35:231-3.
46. Mitra G, Wong MF, Mozen MM, et al. Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion 1986;26:394-7.
47. Wells MA, Wittek AE, Epstein JS, et al. Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion 1986;26:210-3.
48. Remis RS, O'Shaughnessy MV, Tsoukas C, et al. HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrate. Can Med Assoc J 1990;142:1247-54.
49. Heimburger N, Schwinn H, Mauler R. [Factor VIII concentrate, hepatitis-safe: progress in the treatment of hemophilia A.] Gelben Hefte 1980;20:165-74 [NIH Library Translation #NIH 82-59].
50. Heimburger N, Schwinn H, Gratz P, et al. [Factor VIII concentrate, highly purified and heated in solution] (Engl abstract). Arzneimittelforschung 1981;31:619-22 [NIH Library Translation #NIH 82-14].
51. Blood Products Advisory Committee. Transcript for December 4, 1982 meeting. Bethesda, MD: Food and Drug Administration, 1982:137,147-8.
52. Blood Products Advisory Committee. Transcript of February 7, 1983 meeting. Bethesda, MD: Food and Drug Administration, 1983:80.
53. Quinnan GV Jr, Wells MA, Wittek AE, et al. Inactivation of human T-cell lymphotropic virus, type III by heat, chemicals, and irradiation. Transfusion 1986;26:481-3.
54. McDougal JS, Martin LS, Cort SP, et al. Thermal inactivation of the acquired immunodeficiency syndrome virus, human T lymphotropic virus-III/lymphadenopathy-associated virus, with special reference to antihemophilic factor. J Clin Invest 1985;76:875-7.
55. Guo ZP, Yu MW. Hepatitis C virus RNA in factor VIII concentrates. Transfusion 1995;35:112-6.
56. Saldanha J, Minor P. Incidence of hepatitis C virus RNA in anti-HCV-negative plasma pools and blood products. Vox Sang 1996;70:232-4.
57. Fricke W, Augustyniak L, Lawrence D, et al. Human immunodeficiency virus infection due to clotting factor concentrates: results of the Seroconversion Surveillance Project. Transfusion 1992;32:707-9.